Kevin H Eng
Overview
Explore the profile of Kevin H Eng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salgia N, Aubrecht W, Wang L, Ram B, Wasik B, Khan A, et al.
Eur Urol Oncol
. 2024 Mar;
7(5):973-977.
PMID: 38480032
Sarcomatoid renal cell carcinoma (sRCC) is histologically heterogeneous, with variable sarcomatoid amounts intermixed within epithelial carcinoma. However, the current classification for this aggressive disease is homogeneous and agnostic to the...
2.
Sha K, Zhang R, Maolake A, Singh S, Chatta G, Eng K, et al.
bioRxiv
. 2024 Feb;
PMID: 38405929
Androgen deprivation therapy (ADT) is an effective but not curative treatment for advanced and recurrent prostate cancer (PC). We investigated the mechanisms controlling the response to androgen-deprivation by surgical castration...
3.
Holling G, Chavel C, Sharda A, Lieberman M, James C, Lightman S, et al.
Cell Mol Immunol
. 2024 Jan;
21(3):260-274.
PMID: 38233562
Metabolic flexibility has emerged as a critical determinant of CD8+ T-cell antitumor activity, yet the mechanisms driving the metabolic flexibility of T cells have not been determined. In this study,...
4.
Zhang R, Singh S, Pan C, Xu B, Kindblom J, Eng K, et al.
Am J Clin Exp Urol
. 2023 Mar;
11(1):12-26.
PMID: 36923722
Benign prostatic hyperplasia (BPH) is a non-neoplastic proliferative disease producing lower urinary tract symptoms related to the resulting enlarged prostate. BPH is pathologically characterized by hyperplastic growth in both epithelial...
5.
Omole E, Aijaz I, Ellegate Jr J, Isenhart E, Desouki M, Mastri M, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230652
Like BRCA2, MAGEC3 is an ovarian cancer predisposition gene that has been shown to have prognostic significance in ovarian cancer patients. Despite the clinical significance of each gene, no studies...
6.
Oliver L, Alvarez R, Diaz R, Valdes A, Colligan S, Nemeth M, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36150744
Background: Immune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve...
7.
Oturkar C, Gandhi N, Rao P, Eng K, Miller A, Singh P, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267428
High grade serous ovarian cancer (HGSOC) is the most common and lethal subtype of epithelial ovarian cancer. Prevalence (~96%) of mutant p53 is a hallmark of HGSOC. Estrogen receptor-beta (ERβ)...
8.
Khan A, Emmons T, Magner W, Alqassim E, Singel K, Ricciuti J, et al.
Cancer Immunol Immunother
. 2022 Feb;
71(10):2355-2369.
PMID: 35166871
The ovarian tumor microenvironment (TME) is characterized by the accumulation of immunosuppressive tumor-associated macrophages (TAMs) and granulocytic cells. Very small size particles (VSSP), comprised of the ganglioside NAcGM3 and Neisseria...
9.
Ellegate Jr J, Mastri M, Isenhart E, Krolewski J, Chatta G, Kauffman E, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158998
Rare variants in MAGEC3 are associated with BRCA negative, early-onset ovarian cancers. Given this association, we evaluated the impact of MAGEC3 protein expression on prognosis and transcription. We quantified normal...
10.
Mastri M, Ramakrishnan S, Shah S, Karasik E, Gillard B, Moser M, et al.
Am J Clin Exp Urol
. 2022 Jan;
9(6):416-434.
PMID: 34993263
The evolving paradigm of the molecular classification of bladder cancer requires models that represent the classifications with less heterogeneity. Robust transcriptome based molecular classifications are essential to address tumor heterogeneity....